cytarabine has been researched along with Infant, Premature, Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ojha, S; Ooi, MG | 1 |
| Dalinghaus, M; de Vries, AC; Kroon, AA; van den Heuvel-Eibrink, MM; van Dongen, JC | 1 |
| Kimoto, Y; Moritake, H; Nunoi, H; Sawa, D; Shimonodan, H; Yamada, A | 1 |
| Hanshaw, JB | 1 |
1 review(s) available for cytarabine and Infant, Premature, Diseases
| Article | Year |
|---|---|
Herpesvirus hominis infections in the fetus and the newborn.
Topics: Cesarean Section; Cytarabine; Female; Fetal Diseases; Genital Diseases, Female; Herpes Simplex; Herpesviridae Infections; Humans; Idoxuridine; Immunoglobulins; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Interferon Inducers; Pregnancy; Pregnancy Complications, Infectious; Sexually Transmitted Diseases; Simplexvirus | 1973 |
3 other study(ies) available for cytarabine and Infant, Premature, Diseases
| Article | Year |
|---|---|
Pregnancy exposure to midostaurin in the first trimester.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Compassionate Use Trials; Cytarabine; Female; Fetal Growth Retardation; fms-Like Tyrosine Kinase 3; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Leukemia, Myeloid, Acute; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Protein Kinase Inhibitors; Recurrence; Staurosporine; Tandem Repeat Sequences | 2020 |
Successful treatment of congenital acute myeloid leukemia (AML-M6) in a premature infant.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Leukemia, Myeloid, Acute; Remission Induction | 2009 |
Acute megakaryoblastic leukemia and severe pulmonary fibrosis in a child with Down syndrome: successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Biomarkers, Tumor; Cytarabine; Cytokines; Disease Progression; Down Syndrome; Drug Monitoring; Female; GATA1 Transcription Factor; Genetic Predisposition to Disease; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Leukemia, Megakaryoblastic, Acute; Mucin-1; Myeloproliferative Disorders; Neoplasm Proteins; Prednisone; Pulmonary Fibrosis; Remission Induction | 2012 |